Form 4: OrbiMed Entities Report Beneficial Ownership Changes in MBX Biosciences Following IPO

OrbiMed Advisors LLC and related entities report changes in beneficial ownership of MBX Biosciences common stock and convertible preferred stock following the company's initial public offering on September 16, 2024.

Summary

• OrbiMed Advisors LLC, along with OrbiMed Capital GP VII LLC and OrbiMed Genesis GP LLC, filed a Form 4 detailing changes in their beneficial ownership of MBX Biosciences, Inc. (MBX) securities.
• The filing reflects transactions related to MBX Biosciences' initial public offering (IPO) on September 16, 2024.
• Prior to the IPO, OrbiMed held Series A, B, and C Convertible Preferred Stock, which automatically converted into common stock upon the IPO at a ratio of 1-for-12.0221.
• OrbiMed Private Investments VII, LP held 12,372,634 shares of Series A Convertible Preferred Stock, 19,587,284 shares of Series B Convertible Preferred Stock which converted into 1,029,157 and 1,629,271 shares of common stock respectively.
• OrbiMed Genesis Master Fund, L.P. held 4,854,368 shares of Series C Convertible Preferred Stock which converted into 403,787 shares of common stock.
• Following the conversion, OrbiMed Private Investments VII, LP beneficially owns 3,158,428 shares of common stock, and OrbiMed Genesis Master Fund, L.P. beneficially owns 653,787 shares of common stock.
• OrbiMed Private Investments VII, LP purchased 500,000 shares of common stock at $16 per share in the IPO.
• OrbiMed Genesis Master Fund, L.P. purchased 250,000 shares of common stock at $16 per share in the IPO.
• OrbiMed Advisors, as the managing member of both GP VII and Genesis GP, may be deemed to have voting and investment power over the securities held by OPI VII and Genesis Master Fund.
• The reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing reflects standard post-IPO adjustments in ownership, and OrbiMed's participation in the IPO suggests continued confidence in MBX Biosciences.

Positives

• OrbiMed's continued investment in MBX Biosciences, including participation in the IPO, suggests confidence in the company's future prospects.

Risks

• The Form 4 filing itself doesn't inherently indicate risks, but it's important to monitor OrbiMed's future filings for any potential changes in their investment strategy or ownership stake.

Future Outlook

The document does not contain explicit forward-looking statements about MBX Biosciences' future performance, but OrbiMed's continued investment suggests a positive outlook.

Management Comments

• Carl L. Gordon, Sven H. Borho, and W. Carter Neild, members of OrbiMed Advisors' management committee, disclaim beneficial ownership of the shares held by OPI VII and Genesis Master Fund.

Industry Context

This filing is typical for major shareholders following an IPO. It provides transparency into the ownership structure of the company after the initial offering.

Comparison to Industry Standards

• Form 4 filings are standard practice for insiders and major shareholders of publicly traded companies, ensuring transparency and compliance with SEC regulations.
• OrbiMed's investment strategy is comparable to other venture capital and private equity firms specializing in the healthcare sector, such as NEA, Kleiner Perkins, and Flagship Pioneering.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of MBX Biosciences after its IPO.
• The continued investment by OrbiMed may be viewed positively by the market.

Key Dates